Loading patent…
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorsHermona Soreq, Shlomo Seidman, Esther Shohami
Estimating the term…
The invention provides methods and pharmaceutical compositions thereof for treating injury to the central nervous system (CNS). The method includes administering to the CNS of a patient suffering from such an injury a therapeutically effective amount of an inhibitor of acetylcholinesterase (AChE) production immediately following the injury. The methods use as the inhibitor a synthetic nuclease resistant antisense oligonucleotide or ribozyme that is directed against an accessible domain of the AChE mRNA brain variant. The treatment downregulates AChE production and thereby activity. The injury to the CNS may be a head injury (closed or open), brain injury, or spinal cord trauma or other trauma to the CNS.
A method of treating injury to the central nervous system by administering to the central nervous system of a patient suffering from such an injury a therapeutically effective amount of an antisense oligonucleotide of acetylcholinesterase production immediately following the injury whereby acetylcholinesterase activity and production is downregulated.
A method of facilitating transplantation of neuronal cells to the central nervous system of a patient in need of such transplantation by by administering a therapeutically effective amount of an antisense oligonucleotide inhibitor of acethlcholinecterase production at the time of transplant.
A pharmaceutical or medical composition for the treatment of injury to the central nervous system comprising as active ingredient at least one antisense oligonucleotide inhibitor of acetylcholinesterase production in a physiologically acceptable carrier or diluent for the treatment of injury to the central nervous system.
A method of making a synthetic nuclease resistant antisense oligodeoxynucleotide directed against an accessible domain of AChEmRNA synaptic or readthrough variants, said composition being intended for the treatment of injury to the central nervous system, said method comprising the step of combining the synthetic nuclease resistant antisense oligodeoxynucleotides with the physiologically acceptable carrier or diluent.
A method of improving hippocampal neuron survival following injury to the central nervous system by administering to the central nervous system of a patient suffering from such an injury a therapeutically effective amount of an inhibitor of acetylcholinesterase production immediately following the injury.
A method of making a synthetic nuclease resistant antisense oligodeoxynucleotides directed against an accessible domain of AChEmRNA synaptic or readthrough variants, said composition being intended for improving hippocampal neuron survival following injury to the central nervous system, said method comprising the step of combining the synthetic nuclease resistant antisense oligodeoxynucleotides with the physiologically acceptable carrier or diluent.
Dependencies are inferred from the claim text.